ONKONEK anticancer drug

SYNTHERIX Ltd is a new company this year in order to take ONKONEK, a totally new and different way of killing cancer but not normal cells, through preclinical animal studies with the CRUK Institute of Cancer Therapeutics.

£150,000 JUST INVESTED

Past Raises

2023

£350,000

Closed

We act as an investment opportunity aggregator, collecting hundreds of investment opportunities from across the UK.

If you'd like your events, opportunities and news listed here please join free as an organisation.